5 completed, 4 active not recruiting, 1 recruiting, 1 terminated. 12 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 5, Active not recruiting 4, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Shingles: new trials by email Literature Review of Shingles trials Research Report on Shingles
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004 - Herpes Zoster (HZ), Shingles | Phase 2 | Active not recruiting | Guangzhou Patronus Biotech Co., Ltd. | 840 | 2025-10-23 | 2025-12-30 |
| A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine JCXH-105, Shingrix - Herpes Zoster (HZ), Infectious Diseases | Phase 2 | Active not recruiting | Immorna Biotherapeutics, Inc. | 467 | 2024-10-16 | 2026-11-05 |
| Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over Z-1018, Shingrix - Shingles, Herpes Zoster | Phase 1 / Phase 2 | Active not recruiting | Dynavax Technologies Corporation | 764 | 2024-06-17 | 2026-10-16 |
| Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Shingrix - Shingles | Phase 2 | Recruiting | Loyola University | 100 | 2023-03-07 | 2023-03-08 |
| A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection - Shingles, Herpes Zoster Infection | Phase 1 / Phase 2 | Terminated | Pfizer | 484 | 2023-01-25 | 2026-05-04 |
| Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix - Herpes Zoster, Shingles | Phase 2 | Active not recruiting | Curevo Inc | 1516 | 2022-02-02 | 2025-09-30 |
| Systems Biology of Zoster Vaccine Shingrix® - Zoster, Zoster Varicella | Phase 2 | Completed | Emory University | 38 | 2019-11-14 | 2024-07-30 |
| A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster valacyclovir, FV-100, Valacyclovir placebo - Herpes Zoster, Shingles | Phase 2 | Completed | Bristol-Myers Squibb | 350 | 2009-05-01 | 2015-10-12 |
| A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) KD7040 Topical Gel, Placebo gel - Postherpetic Neuralgia, Shingles | Phase 2 | Completed | Kalypsys, Inc. | 48 | 2007-11-01 | 2008-07-22 |
| Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia REN-1654 - Neuralgia, Shingles | Phase 2 | Unknown | Renovis | 90 | 2003-08-01 | 2010-07-29 |
| Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007) zoster vaccine live (Oka/Merck), Comparator: placebo (unspecified) - Shingles | Phase 2 | Completed | Merck Sharp & Dohme LLC | 180 | 2001-11-01 | 2017-03-15 |
| NGX-4010 for the Treatment of Postherpetic Neuralgia Capsaicin Dermal Patch - Herpes Zoster, Neuralgia | Phase 2 / Phase 3 | Completed | NeurogesX | 300 | 2008-03-06 |
Herpes Zoster (12) · Chickenpox (4) · Neuralgia (3) · Neuralgia, Postherpetic (2) · Peripheral Nervous System Diseases (2) · Communicable Diseases (1) · Hyperalgesia (1) · Pain (1) · Vaccine-Preventable Diseases (1)
DNA Virus Infections (12) · Herpesviridae Infections (12) · Infections (12) · Varicella Zoster Virus Infection (12) · Virus Diseases (12) · Pathological Conditions, Signs and Symptoms (4) · Nervous System Diseases (3) · Neurologic Manifestations (3) · Neuromuscular Diseases (3) · Signs and Symptoms (3) · Pain (2) · Disease Attributes (1) · Pathologic Processes (1) · Peripheral Nervous System Diseases (1) · Sensation Disorders (1)
Antigens (1) · FV-100 (1) · Herpes Zoster Vaccine (1) · Injections (1) · Suspensions (1) · Valacyclovir (1)
Bristol-Myers Squibb (1) · Curevo Inc (1) · Dynavax Technologies Corporation (1) · Emory University (1) · Guangzhou Patronus Biotech Co., Ltd. (1) · Immorna Biotherapeutics, Inc. (1) · Kalypsys, Inc. (1) · Loyola University (1) · Merck Sharp & Dohme LLC (1) · NeurogesX (1) · Pfizer (1) · Renovis (1)
United States (8) · Australia (1) · China (1) · New Zealand (1)
Guy De La Rosa, MD (1) · Lisa Shelton, ARNP (1) · Nadine Rouphael, MD (1) · Randall W Moreadith, MD, PhD (1) · Tao Huang (1)
U19AI090023 (1)